M. M. Oken

953 total citations
19 papers, 734 citations indexed

About

M. M. Oken is a scholar working on Pathology and Forensic Medicine, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. M. Oken has authored 19 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 7 papers in Hematology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. M. Oken's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). M. M. Oken is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). M. M. Oken collaborates with scholars based in United States. M. M. Oken's co-authors include Barbara L. Braun, David M. Murray, Janice Post‐White, Thomas E. Elliott, Daniel Weisdorf, Claire Pomeroy, Karen M. Johnson, Kathryn L. Lunetta, Angela Panoskaltsis‐Mortari and Anna M. Masellis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Medicine.

In The Last Decade

M. M. Oken

19 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. M. Oken United States	13	270	250	167	159	149	19	734
B. Johansson Sweden	18	133 0.5×	214 0.9×	331 2.0×	165 1.0×	39 0.3×	43	1.0k
E. S. Henderson United States	17	352 1.3×	304 1.2×	193 1.2×	226 1.4×	162 1.1×	33	909
Gita Massey United States	14	678 2.5×	79 0.3×	68 0.4×	162 1.0×	308 2.1×	40	1.1k
H. Köppler Germany	19	211 0.8×	382 1.5×	297 1.8×	283 1.8×	72 0.5×	66	872
Jennifer M. Bird United Kingdom	14	693 2.6×	356 1.4×	47 0.3×	114 0.7×	101 0.7×	23	918
Elena Del Ferro Italy	14	153 0.6×	277 1.1×	64 0.4×	41 0.3×	92 0.6×	22	794
R Powles United Kingdom	19	645 2.4×	258 1.0×	54 0.3×	124 0.8×	310 2.1×	52	1.1k
J. Abels Netherlands	14	621 2.3×	171 0.7×	28 0.2×	149 0.9×	243 1.6×	29	896
Gianluigi Cetto Italy	16	61 0.2×	291 1.2×	173 1.0×	53 0.3×	78 0.5×	43	675
Margaret Masterson United States	15	600 2.2×	139 0.6×	42 0.3×	143 0.9×	263 1.8×	41	930

Countries citing papers authored by M. M. Oken

Since Specialization

Citations

This map shows the geographic impact of M. M. Oken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. M. Oken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. M. Oken more than expected).

Fields of papers citing papers by M. M. Oken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. M. Oken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. M. Oken. The network helps show where M. M. Oken may publish in the future.

Co-authorship network of co-authors of M. M. Oken

This figure shows the co-authorship network connecting the top 25 collaborators of M. M. Oken. A scholar is included among the top collaborators of M. M. Oken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. M. Oken. M. M. Oken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Oken, M. M., et al.. (2001). Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 91(7). 1219–1230. 100 indexed citations

Oken, M. M., Traci Leong, Raymond E. Lenhard, et al.. (1999). The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. Cancer. 86(6). 957–968. 39 indexed citations

Mandel, Jeffrey S. & M. M. Oken. (1998). Etiology, prevention, and treatment of breast, prostate, colorectal, and lung cancer.. PubMed. 81(5). 44–6, 71. 1 indexed citations

Elliott, Thomas E., David M. Murray, M. M. Oken, et al.. (1997). Improving cancer pain management in communities: Main results from a randomized controlled trial. Journal of Pain and Symptom Management. 13(4). 191–203. 69 indexed citations

Oken, M. M., et al.. (1996). Prophylactic antibiotics for the prevention of early infection in multiple myeloma. The American Journal of Medicine. 100(6). 624–628. 83 indexed citations

Mazza, J. J., John Hines, Janet W. Andersen, et al.. (1995). Aggressive Chemotherapy in the Treatment of Burkitt's and Non-BurKitt's Undifferentiated Lymphoma. Leukemia & lymphoma. 18(3-4). 289–296. 5 indexed citations

Elliott, Thomas E., David M. Murray, Barbara A. Brown‐Elliott, et al.. (1995). Physician knowledge and attitudes about cancer pain management: A survey from the Minnesota cancer pain project. Journal of Pain and Symptom Management. 10(7). 494–504. 89 indexed citations

Fisher, Richard I. & M. M. Oken. (1995). Clinical practice guidelines: non-Hodgkin's lymphomas. Cleveland Clinic Journal of Medicine. 62(Supplement_1). S1–6. 10 indexed citations

Lenhard, Raymond E., Michael J. Daniels, M. M. Oken, et al.. (1994). An Aggressive High Dose Cyclophosphamide and Prednisone Regimen for Advanced Multiple Myeloma. Leukemia & lymphoma. 13(5-6). 485–489. 6 indexed citations

10.

Hamm, John, et al.. (1994). Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.. Journal of Clinical Oncology. 12(12). 2667–2676. 40 indexed citations

11.

Fisher, Richard I., Ellen R. Gaynor, Steve Dahlberg, et al.. (1994). A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Annals of Oncology. 5. S91–S95. 76 indexed citations

12.

Vogler, William R., David P. Harrington, E. Winton, et al.. (1992). Phase II clinical trial of carboplatin in relapsed and refractory leukemia.. PubMed. 6(10). 1072–5. 18 indexed citations

13.

Rowe, Jacob M., J. W. Andersen, Peter A. Cassileth, et al.. (1992). Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience.. PubMed. 6 Suppl 4. 75–7. 6 indexed citations

14.

Cummings, F J, Ki Wook Kim, Richard S. Neiman, et al.. (1991). Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.. Journal of Clinical Oncology. 9(4). 565–571. 71 indexed citations

15.

Kay, Neil E., M. M. Oken, J. J. Mazza, & E C Bradley. (1988). Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2.. PubMed. 30(5-6). 475–8. 18 indexed citations

16.

Trump, D L, Paul Elson, Ernest C. Borden, et al.. (1987). High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.. PubMed. 71(2). 165–9. 21 indexed citations

17.

Cassileth, Peter A., C B Begg, R Silber, et al.. (1987). Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.. PubMed. 71(2). 137–40. 35 indexed citations

18.

Oken, M. M. & Manuel E. Kaplan. (1979). Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia.. PubMed. 63(3). 441–7. 36 indexed citations

19.

Schorer, Anna E., M. M. Oken, & G. J. Johnson. (1978). Gynecomastia with nitrosourea therapy.. PubMed. 62(4). 574–6. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact